/PRLD

PRLD Stock - Prelude Therapeutics Incorporated

Q: What is the analyst price target for PRLD?

Analyst price target information is not currently available for PRLD.

Q: What is PRLD's market cap?

Market capitalization information is not currently available for PRLD.

Healthcare|Biotechnology|NASDAQ

$2.14+11.46%

+$0.22 (+11.46%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

High Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

100

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

100

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+273.8%upside

Target: $8.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for PRLD

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.06

52W High$4.22

52W Low$0.61

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$7.00M	N/A	N/A	N/A	N/A
Gross Profit	$7.00M	N/A	N/A	N/A	N/A
Gross Margin	100.0%	N/A	N/A	N/A	N/A
Operating Income	$-139,714,000	$-132,276,999	$-123,540,000	$-113,735,000	$-58,763,000
Net Income	$-127,173,000	$-121,832,000	$-115,438,000	$-111,694,000	$-56,929,000
Net Margin	-1816.8%	N/A	N/A	N/A	N/A
EPS	$-1.68	$-2.02	$-2.27	$-2.33	$-1.30

Company Overview

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6; and PRT-K4 that is in preclinical stage for solid tumors. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

50%

Hold / Neutral

33%

Sell / Underperform

17%

Analyst Consensus🟡 Mixed

3 Bullish3 Neutral/Bearish

Price Targets

Average Target

↑ 192.1% Upside

Now

Low

Average

$11

High

Based on 8 analysts

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
September 19th 2024	H.C. Wainwright	Upgrade	Buy	$5
June 20th 2024	Barclays	Downgrade	Underweight	$3
March 13th 2024	JMP Securities	Initiation	Mkt Outperform	$7
February 20th 2024	H.C. Wainwright	Downgrade	Neutral	$5
December 19th 2023	Morgan Stanley	Downgrade	Underweight	$4← $10
November 21st 2022	BofA Securities	Downgrade	Underperform	$6← $8
September 9th 2022	Morgan Stanley	Downgrade	Equal Weight	$11← $19
July 29th 2022	Jefferies	Initiation	Buy	$9

Earnings History & Surprises

PRLD

Beat Rate

72%

Last 18 quarters

Avg Surprise

+7.8%

EPS vs Estimate

Beats / Misses

13/3

2 met exactly

Latest EPS

$-0.26

Q4 2025

EPS Surprise History

Q1 24

+6.0%

$-0.47vs$-0.50

Q2 24

+10.6%

$-0.42vs$-0.47

Q3 24

0.0%

$-0.46vs$-0.46

Q4 24

+10.4%

$-0.43vs$-0.48

Q1 25

+22.4%

$-0.38vs$-0.49

Q2 25

+10.6%

$-0.42vs$-0.47

Q3 25

+8.9%

$-0.41vs$-0.45

Q4 25

+25.7%

$-0.26vs$-0.35

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2026	May 4, 2026	—	—	—	—
Q1 2026	Mar 9, 2026	$-0.33	—	—	—
Q4 2025	Nov 12, 2025	$-0.35	$-0.26	+25.7%	✓ BEAT
Q3 2025	Aug 14, 2025	$-0.45	$-0.41	+8.9%	✓ BEAT
Q2 2025	May 6, 2025	$-0.47	$-0.42	+10.6%	✓ BEAT
Q1 2025	Mar 10, 2025	$-0.49	$-0.38	+22.4%	✓ BEAT
Q4 2024	Nov 6, 2024	$-0.48	$-0.43	+10.4%	✓ BEAT
Q3 2024	Aug 12, 2024	$-0.46	$-0.46	0.0%	= MET
Q2 2024	May 7, 2024	$-0.47	$-0.42	+10.6%	✓ BEAT
Q1 2024	Feb 15, 2024	$-0.50	$-0.47	+6.0%	✓ BEAT
Q4 2023	Nov 1, 2023	$-0.58	$-0.45	+22.4%	✓ BEAT
Q3 2023	Aug 3, 2023	$-0.65	$-0.54	+16.9%	✓ BEAT
Q2 2023	May 8, 2023	$-0.68	$-0.58	+14.7%	✓ BEAT
Q1 2023	Mar 15, 2023	$-0.63	$-0.60	+4.8%	✓ BEAT
Q4 2022	Nov 14, 2022	$-0.63	$-0.63	0.0%	= MET
Q3 2022	Aug 9, 2022	$-0.60	$-0.58	+3.3%	✓ BEAT
Q2 2022	May 10, 2022	$-0.68	$-0.63	+7.4%	✓ BEAT
Q1 2022	Mar 16, 2022	$-0.69	$-0.71	-2.9%	✗ MISS
Q4 2021	Nov 12, 2021	$-0.62	$-0.66	-6.5%	✗ MISS
Q3 2021	Aug 12, 2021	$-0.51	$-0.58	-13.7%	✗ MISS

Frequently Asked Questions about PRLD

What is PRLD's current stock price?

Prelude Therapeutics Incorporated (PRLD) is currently trading at $2.14 per share. The stock has moved +11.46% today.

What is the analyst price target for PRLD?

The average analyst price target for PRLD is $8.00, based on 1 analyst.

What sector is Prelude Therapeutics Incorporated in?

Prelude Therapeutics Incorporated operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is PRLD's market cap?

Prelude Therapeutics Incorporated has a market capitalization of $0.12 billion, making it a small-cap company.

Does PRLD pay dividends?

No, Prelude Therapeutics Incorporated does not currently pay a dividend to shareholders.